 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | uttroside-B (Utt-B) / Q BioMed
Journal, Orphan drug: A Novel Combinatorial Regimen Using Sorafenib and Uttroside B, A US FDA-designated 'Orphan Drug', for the Treatment of Hepatocellular Carcinoma. (Pubmed Central) - Aug 12, 2024
Our results highlight the potential of Utt-B as an effective chemosensitizer, which can augment the efficacy of Sor against HCC and circumvent Sor-induced toxic side effects. Moreover, this is the first and only report to date on the chemosensitizing potential of Utt-B and the only report that demonstrates the therapeutic efficacy and pharmacological safety of a novel combinatorial regimen involving Utt-B and Sor for combating HCC.
- || uttroside-B (Utt-B) / Q BioMed
PK/PD data, Journal: Enhanced extracellular vesicles mediated uttroside B (Utt-B) delivery to Hepatocellular carcinoma cell: Pharmacokinetics based on PBPK modelling. (Pubmed Central) - Mar 11, 2024
We further analysed drug-releasing kinetics and simulated the Pharmacokinetics by PBPK modelling. The simulated pharmacokinetics revealed the bioavailability of Uttroside-B in oral administration against intravenous administration.
- || uttroside-B (Utt-B) / Q BioMed
Review, Journal: Solanum nigrum Linn.: Advances in anti-cancer activity and mechanism in digestive system tumors. (Pubmed Central) - Oct 4, 2023
include solanine, solasonine, solamargine, a-L-rhhamnopyranose, uttroside B, degalactotigonin, glycoprotein, and other compounds...nigrum Linn. has great potential in the treatment of tumors of the digestive system, and through further clinical trials and pharmacological mechanisms it has the potential to become a uniform and standardized anti-tumor drug.
- uttroside-B / Q BioMed
The phyto-saponin, Uttroside B, displays an augmented therapeutic index over sorafenib in a pre-clinical model of hepatocellular carcinoma (Poster Area) - Jun 28, 2022 - Abstract #EACR2022EACR_692;
Conclusion Our data demonstrate the superior therapeutic index of Utt-B over sorafenib against HCC. Clinical studies in HCC patients utilizing Utt-B, which now holds the U.S. FDA approval as an 'orphan drug’ is an essential step to promote this drug from bench to bedside.
- uttroside-B / Q BioMed
Impedance of autophagy improves the potency of uttroside B, a US FDA-approved 'orphan drug' against hepatocellular carcinoma (Poster Area) - Jun 28, 2022 - Abstract #EACR2022EACR_691;
Conclusion Our results suggest that Utt-B is a more potent anti-HCC drug than sorafenib and the antitumor effect of Utt-B against HCC can be further enhanced by blocking autophagy. Hence, Utt-B in combination with Cqn, a clinically approved drug, if repurposed and used in a combinatorial regimen with Utt-B, can further improve the therapeutic efficacy of Utt-B against HCC.
- | uttroside-B / Q BioMed, Nexavar (sorafenib) / Bayer, Amgen
Preclinical, Journal: Augmented Efficacy of Uttroside B over Sorafenib in a Murine Model of Human Hepatocellular Carcinoma. (Pubmed Central) - May 30, 2022
Here, we show that higher concentrations of sorafenib induce severe toxicity, in Chang Liver, as well as in acute and chronic in vivo models, indicating that, apart from the superior therapeutic benefit over sorafenib, Utt-B is a pharmacologically safer molecule, and the drug-induced undesirable effects can, thus, be substantially alleviated in the context of HCC chemotherapy. Clinical studies in HCC patients utilizing Utt-B, is a contiguous key step to promote this drug to the clinic.
- | uttroside-B / Q BioMed
Journal: Blockade of Uttroside B-Induced Autophagic Pro-Survival Signals Augments Its Chemotherapeutic Efficacy Against Hepatocellular Carcinoma. (Pubmed Central) - Feb 26, 2022
Taken together, our results suggest that the antitumor effect of Utt-B against HCC can be further enhanced by blocking autophagy. Furthermore, Utt-B in combination with Cqn, a clinically approved drug, if repurposed and used in a combinatorial regimen with Utt-B, can further improve the therapeutic efficacy of Utt-B against HCC.
- || uttroside B / Q BioMed
#QBioMed's Uttroside-B Receives U.S. Patent in Treatment of #LiverCancer $QBIO https://t.co/uTsszt0SLv (Twitter) - Nov 18, 2020
- | uttroside B / Q BioMed
Journal: Emerging themes of regulation of oncogenic proteins by Solanum nigrum and its bioactive molecules in different cancers. (Pubmed Central) - Dec 6, 2019
Several worthy of mention include uttroside B, solanine, solamargine, and physalins, which have been tested for efficacy in cancer cell lines and xenografted mice...We also provide an overview of new tools, methodologies, and approaches, which will allow researchers to extract as much information as possible out of the tremendous data sets currently being generated. The use of computational tools will be helpful in processing structurally complex natural products and also in prediction of their macromolecular targets.